GlassScriptPhysician profile
Adam A Paduszynski
NPI 1609869650
$1,555.89
in general payments reported to CMS, 2019-2025
25 companies · $366 in 2025
The $366 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.43 · 2020: $131 · 2021: $190 · 2022: $15.00 · 2023: $333 · 2024: $462 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,160.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $247.27 | 2020-2024 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $245.49 | 2019-2025 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $238.29 | 2023-2025 | Darzalex, Talvey, Erleada |
| Janssen Pharmaceuticals, INC | $163.91 | 2021-2025 | Darzalex, Tecvayli, Talvey |
| Aveo Pharmaceuticals, INC. | $67.35 | 2023-2025 | Fotivda |
| E.R. Squibb & Sons, L.L.C. | $56.69 | 2020-2023 | Opdivo |
| Novartis Pharmaceuticals Corporation | $55.93 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.96 | 2020-2023 | |
| Regeneron Healthcare Solutions, INC. | $48.13 | 2023-2025 | Libtayo |
| Lilly USA, LLC | $45.58 | 2020-2025 | Jaypirca, Verzenio |
| Novocure INC. | $35.38 | 2023 | Optune |
| Astellas Pharma US INC | $34.90 | 2021-2023 | Padcev |
| Lexicon Pharmaceuticals, INC. | $33.74 | 2020 | |
| Pfizer INC. | $31.78 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $23.20 | 2024 | Rezlidhia, Tavalisse |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $22.26 | 2024 | Xpovio |
| Apellis Pharmaceuticals, INC. | $21.93 | 2023 | Empaveli |
| Tersera Therapeutics LLC | $19.06 | 2024 | Xermelo |
| Array Biopharma INC | $18.75 | 2023 | Braftovi, Comirnaty, Paxlovid |
| Taiho Oncology, INC. | $17.81 | 2025 | |
| Eisai INC. | $16.50 | 2024 | |
| Celltrion USA INC. | $16.05 | 2023 | Vegzelma |
| Octapharma USA, INC. | $15.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.99 | 2021 | |
| Emd Serono, INC. | $12.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Paduszynski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.